Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior

Background: Lenvatinib, a tyrosine kinase inhibitor (TKI) approved for the treatment of progressive and radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), is associated with significant adverse effects that can be partially mitigated through the development of novel drug formul...

Descripción completa

Detalles Bibliográficos
Autores principales: Revilla, Giovanna, Al Qtaish, Nuseibah, Caruana, Pablo, Sainz-Ramos, Myriam, Lopez-Mendez, Tania, Rodriguez, Francisco, Paez-Espinosa, Verónica, Li, Changda, Vallverdú, Núria Fucui, Edwards, Maria, Moral, Antonio, Pérez, José Ignacio, Escolà-Gil, Juan Carlos, Pedraz, José Luis, Gallego, Idoia, Corcoy, Rosa, Céspedes, María Virtudes, Puras, Gustavo, Mato, Eugènia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668968/
https://www.ncbi.nlm.nih.gov/pubmed/38002329
http://dx.doi.org/10.3390/biom13111647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668968/
https://www.ncbi.nlm.nih.gov/pubmed/38002329
http://dx.doi.org/10.3390/biom13111647

Ejemplares similares